Teach More Business in School

Science, medicine and information technology have become intimately entangled with business on all levels. Whether in academic settings or business settings, success in these areas increasingly requires involvement with basic business concepts and principles that aren’t taught in college.

Undergraduates in science and engineering disciplines graduate from universities and enter positions in biotechnology and technology startups with almost no exposure to business concepts. While they may have had an economics course here or there, most have never been exposed to accounting principles, organizational behavior concepts, leadership principles, negotiation, market strategy, and finance. Even those who enter PhD programs will eventually have to manage a budget and lead a lab, whether academic or in a commercial setting. The successful scientist and/or engineer will eventually learn some of this by osmosis or concerted effort, but will often feel at a disadvantage from their colleagues in business disciplines who understand the “arcane” world of business, seemingly by second nature.

Education of science, technology, engineering and math (STEM) students at the undergraduate level should include exposure to the basic principles of business. With various departments vying for time in the 120 graduation credits, it may not be possible to devote a full time course to this. In this day of online courses and MOOCs, it should be quite easy to have students complete a basic business introduction during their vacations or summers. Perhaps, like physical education requirements, a student could “place out” by taking an exam.

The purpose of undergraduate education is not to create experts in subject areas. STEM undergraduates should get a broad exposure to the humanities and social sciences so that they can be familiar with, and conversant in the language of multiple disciplines upon graduation and ready for post-graduate training (academic or otherwise) in their area of concentration. A business course which simply enables a college graduate to understand the context and framework for a business discussion would pay dividends for both the STEM graduates and their employers.

[Editor’s note: To tap the wisdom of our distinguished group of Xconomists, we asked a few of them to answer this question heading into 2015: “If you could change one thing in education, what would it be?” You can see more questions and answers here.]

Author: Paul A. Bleicher

Paul Bleicher, MD, PhD, is the Chief Executive Officer of Optum Labs, an open, collaborative health care innovation center established by Mayo Clinic and Optum to attract research partnerships between various stakeholder groups in healthcare and accelerate the “speed of innovation” in the pursuit of improved patient health. Previously he was Chief Medical Officer for Humedica, a next-generation clinical informatics company that provides novel business intelligence solutions to the health care and life science industry. At Humedica, he had responsibility for medical informatics, data analytics and consulting, and product development. Prior to joining the founding team of Humedica, he was the founder and chairman of Phase Forward, where he grew the organization over an 11-year period from concept to a publicly traded company that is a leading provider of integrated clinical trial data management software and safety solutions for the biopharmaceutical industry. He was the original CEO of Phase Forward (acquired by Oracle in 2010), and throughout his tenure there focused on corporate strategy. Until his departure in October 2008, he served continuously as chairman. Before Phase Forward, Dr. Bleicher served as vice president of Clinical Affairs at Alpha-Beta Technology, and director, Early Phase Services at PAREXEL International. Dr. Bleicher received his MD and PhD from the University of Rochester School of Medicine and Dentistry, specializing in cellular immunology, and his BS from Rensselaer Polytechnic Institute. He trained in internal medicine at the Beth Israel Hospital, and dermatology at Harvard Medical School/Massachusetts General Hospital, did a post-doctoral fellowship at the Dana Farber Cancer Institute in molecular biology, and began his career as a physician/investigator and assistant professor at the Massachusetts General Hospital and Harvard Medical School.